Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

Launched by KHYBER MEDICAL COLLEGE, PESHAWAR · Jul 9, 2025

Keywords

ClinConnect Summary

This study tests whether a once-weekly diabetes medicine called Trelagliptin works as well as a daily medicine called Sitagliptin for people with type 2 diabetes who are already taking metformin but still have higher than target blood sugar. Over 3 months, participants are randomly assigned to receive either Trelagliptin 100 mg once a week or Sitagliptin 100 mg once daily, in addition to continuing metformin. The main question is whether Trelagliptin lowers average blood sugar (measured by HbA1c) as well as Sitagliptin after 3 months, and whether it helps keep blood sugar from fluctuating. The study also looks at whether weekly dosing helps people take their medicine more reliably and whether they are more satisfied with their treatment.

Who can join: adults and others with type 2 diabetes who are on metformin but not at target, with HbA1c roughly between 6.5% and 10%, and who are willing to participate. Key exclusions include type 1 diabetes, pregnancy, major kidney or heart problems, cancer, or already taking Trelagliptin or in another trial. The trial is at Khyber Teaching Hospital in Peshawar, Pakistan. Participants will have blood tests (HbA1c at 3 months, fasting sugar, and blood sugar 2 hours after breakfast), keep a diary of their pill use, and answer a satisfaction questionnaire. About 126 people may enroll, starting around July 2025, with the study expected to finish by December 2026.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Type 2 Diabetic patients visiting Medical OPD
• • Patients already maintaining lifestyle modifications and on metformin monotherapy, but not achieving target HbA1c levels.
• • Patients who require treatment with a DPP-4 inhibitors
• • Patients with baseline HbA1c \> 6.5% and \< 10%
• • Patients willing to provide written informed consent prior to recruitment
• Exclusion Criteria:
• • • Type 1 Diabetic Patients
• • Patients already using Trelagliptin for type 2 diabetes
• • Patients with severe renal impairment (eGFR \< 30ml/min/1.73m2 or on dialysis)
• • Patients with Serious Heart disease or Cerebrovascular disease
• • Patients with Serious Pancreatic or blood disease
• • Patients with malignancy
• • Patients with history of hypersensitivity to DPP-4 inhibitors
• • Patients with history of gastrointestinal resection
• • Pregnant, Breast feeding or planning to be pregnant patients
• • Patients participating in other clinical studies
• • Patients assessed as ineligible by researchers due to any other reason